pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
LILLY · news · pharmadog
← back to LILLY
News mentioning LILLY
792
stories
28d
Mistrust in science and a juicy gene-editing lawsuit
stat
28d
3 takeaways from a European obesity scientific meeting
biopharma dive
28d
Lilly, Foghorn part ways; Wave’s FDA-approved plans
biopharma dive
29d
Pfizer’s eczema drug clears skin in mid-stage trial
biopharma dive
29d
Foghorn lays off 40% of staff after Lilly collaboration ends
biospace
29d
Fresenius Kabi manufacturing plant hit with FDA warning letter after adverse events
biospace
29d
Zealand dips as Boehringer Ingelheim-partnered weight loss drug fails to impress—again
biospace
29d
Lilly pulls back from Foghorn's synthetic lethality work as biotech sheds 40% of staff
endpoints
29d
STAT+: Pharmalittle: We’re reading about a plan to lower Medicare drug prices, a Lilly obesity drug, and more
stat
29d
M&A slows in Q3 but Vertex snags one of the year’s biggest in $10B Crinetics buy
biospace
29d
Foghorn lays off 40% of employees as Lilly cancer collab collapses over poor data
fiercebiotech
29d
The top 12 companies hiring in biopharma now
biospace
29d
Recon: Sanofi, Regeneron expand partnership after Dupixent success; Lilly amylin-Zepbound combo succeeds in mid-stage trial
raps
Sep 30, 26
Superior weight loss, blood sugar control propel Lilly’s amylin-GIP/GLP-1 combo into Phase 3
biospace
Sep 30, 26
#EASD26: Lilly's amylin-Zepbound combo posts best-ever weight loss in patients with obesity and diabetes
endpoints
Sep 30, 26
STAT+: Eli Lilly’s Zepbound combined with amylin drug led to significant weight loss in mid-stage trial
stat
Sep 30, 26
Lilly builds commercial case for GLP-1 products over Novo with indirect analyses
biospace
Sep 30, 26
Lilly raises diabetes weight-loss bar with amylin-Zepbound combo
fiercebiotech
Sep 30, 26
AstraZeneca buys into Summit, UniQure drops on 4-year data, FDA on a roll
biospace
Sep 30, 26
Roche, Zealand see phase 2 amylin weight loss peak at mid-dose, start pivotal program
fiercebiotech
Sep 30, 26
Trend of women-led M&A fades in 2026 with just two deals so far
biospace
Sep 30, 26
Lilly sets up next-gen obesity battle with full phase 3 retatrutide data
fiercebiotech
Sep 29, 26
#EASD26: Zealand and Roche's amylin works best at middle dose, trails Lilly's
endpoints
Sep 29, 26
#EASD26: Lilly's triple-G allows 60% of patients to drop below obesity threshold
endpoints
Sep 29, 26
STAT+: Overton won’t get a vote before midterms
stat
Sep 29, 26
Novo to pay Hengrui up to $2.6B for a once-weekly obesity pill
biopharma dive
Sep 29, 26
Roche cuts muscle-sparing obesity drug after mid-stage disappointment
biospace
Sep 29, 26
STAT+: AstraZeneca invests $2 billion in Summit Therapeutics
stat
Sep 29, 26
STAT+: Pharmalittle: We’re reading about Novo licensing a Chinese obesity pill, Merck pulling an antibiotic, and more
stat
Sep 29, 26
STAT+: UniQure’s gene therapy continues to slow Huntington’s progression after four years
stat
← prev
page 6 of 27
next →
